|
US4160452A
(en)
|
1977-04-07 |
1979-07-10 |
Alza Corporation |
Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
|
|
US4256108A
(en)
|
1977-04-07 |
1981-03-17 |
Alza Corporation |
Microporous-semipermeable laminated osmotic system
|
|
US4265874A
(en)
|
1980-04-25 |
1981-05-05 |
Alza Corporation |
Method of delivering drug with aid of effervescent activity generated in environment of use
|
|
US4623652A
(en)
*
|
1981-11-12 |
1986-11-18 |
American Hospital Supply Corporation |
Esters of thiadiazole oxypropanolaine derivatives and pharmaceutical uses
|
|
US4623662A
(en)
*
|
1985-05-23 |
1986-11-18 |
American Cyanamid Company |
Antiatherosclerotic ureas and thioureas
|
|
US5007790A
(en)
|
1989-04-11 |
1991-04-16 |
Depomed Systems, Inc. |
Sustained-release oral drug dosage form
|
|
US5169645A
(en)
|
1989-10-31 |
1992-12-08 |
Duquesne University Of The Holy Ghost |
Directly compressible granules having improved flow properties
|
|
WO1991013871A1
(fr)
*
|
1990-03-12 |
1991-09-19 |
Yamanouchi Pharmaceutical Co., Ltd. |
Derive de monouree et ses sels
|
|
US5582837A
(en)
|
1992-03-25 |
1996-12-10 |
Depomed, Inc. |
Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
|
|
ATE173159T1
(de)
|
1992-03-25 |
1998-11-15 |
Depomed Systems Inc |
Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe
|
|
EP0634402A1
(en)
*
|
1993-07-14 |
1995-01-18 |
Takeda Chemical Industries, Ltd. |
Isochinolinone derivatives, their production and use
|
|
US6211373B1
(en)
*
|
1996-03-20 |
2001-04-03 |
Smithkline Beecham Corporation |
Phenyl urea antagonists of the IL-8 receptor
|
|
WO1997047285A1
(en)
|
1996-06-10 |
1997-12-18 |
Depomed, Inc. |
Gastric-retentive oral controlled drug delivery system with enhanced retention properties
|
|
US5972389A
(en)
|
1996-09-19 |
1999-10-26 |
Depomed, Inc. |
Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
|
|
WO1998033501A1
(en)
|
1997-01-31 |
1998-08-06 |
Avid Therapeutics Inc. |
2-benzoylamino-3-phenylpropenamide derivatives and methods of using the same
|
|
US6635280B2
(en)
|
1997-06-06 |
2003-10-21 |
Depomed, Inc. |
Extending the duration of drug release within the stomach during the fed mode
|
|
ES2248908T7
(es)
|
1997-06-06 |
2014-11-24 |
Depomed, Inc. |
Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles
|
|
US6323219B1
(en)
|
1998-04-02 |
2001-11-27 |
Ortho-Mcneil Pharmaceutical, Inc. |
Methods for treating immunomediated inflammatory disorders
|
|
NZ518739A
(en)
|
1999-11-02 |
2004-12-24 |
Depomed Inc |
Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
|
|
PT1251832E
(pt)
|
2000-02-04 |
2007-01-31 |
Depomed Inc |
Forma de dosagem constituída por invólucro-e-núcleo que conduz a uma libertação do fármaco de ordem zero
|
|
US6488962B1
(en)
|
2000-06-20 |
2002-12-03 |
Depomed, Inc. |
Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
|
|
US6451808B1
(en)
|
2000-10-17 |
2002-09-17 |
Depomed, Inc. |
Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
|
|
US20030031711A1
(en)
|
2001-05-29 |
2003-02-13 |
Fara John W. |
Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough
|
|
US20030091630A1
(en)
|
2001-10-25 |
2003-05-15 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
|
|
TWI312285B
(en)
|
2001-10-25 |
2009-07-21 |
Depomed Inc |
Methods of treatment using a gastric retained gabapentin dosage
|
|
CA2409552A1
(en)
|
2001-10-25 |
2003-04-25 |
Depomed, Inc. |
Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
|
|
JP2005508358A
(ja)
|
2001-10-25 |
2005-03-31 |
デポメド・インコーポレイテッド |
胃滞留型ロサルタン投与量を用いる治療方法
|
|
US6723340B2
(en)
|
2001-10-25 |
2004-04-20 |
Depomed, Inc. |
Optimal polymer mixtures for gastric retentive tablets
|
|
US6682759B2
(en)
|
2002-02-01 |
2004-01-27 |
Depomed, Inc. |
Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
|
|
CL2004000234A1
(es)
|
2003-02-12 |
2005-04-15 |
Biogen Idec Inc |
Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
|
|
EP1739078A1
(de)
|
2005-05-30 |
2007-01-03 |
Jerini AG |
C5a-Rezeptor-Antagonisten
|
|
US7951789B2
(en)
|
2006-12-28 |
2011-05-31 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
|
AR070127A1
(es)
|
2008-01-11 |
2010-03-17 |
Novartis Ag |
Pirrolo - pirimidinas y pirrolo -piridinas
|
|
US8816074B2
(en)
|
2009-11-16 |
2014-08-26 |
University of Georgia Foundation, Inc. |
2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
|
|
WO2011062955A2
(en)
*
|
2009-11-18 |
2011-05-26 |
University Of Massachusetts |
Compounds for modulating tlr2
|
|
EP2552893B1
(en)
*
|
2010-03-31 |
2014-10-29 |
Actelion Pharmaceuticals Ltd. |
Antibacterial isoquinolin-3-ylurea derivatives
|
|
CL2011000716A1
(es)
|
2010-03-31 |
2012-04-20 |
Gilead Pharmasset Llc |
Formas cristalinas 1 6 de (s)-isopropil-2-(((s)-(((2r.3r.4r.5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1(2h)-il)-4-fluoro-3-hidroxi-4-metil tetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato; composicion y combinacion farmaceutica; y su uso para tratar una infeccion por el virus de la hepatitis c.
|
|
CN103889428A
(zh)
|
2010-10-04 |
2014-06-25 |
肝炎与病毒研究所 |
乙型肝炎病毒抗原分泌的新型抑制剂
|
|
JP6165723B2
(ja)
|
2011-06-30 |
2017-07-19 |
アローヘッド ファーマシューティカルズ インコーポレイテッド |
Ｂ型肝炎ウイルスの遺伝子発現を阻害するための組成物および方法
|
|
JP5977347B2
(ja)
|
2011-07-01 |
2016-08-24 |
バルーク エス．ブルームバーグ インスティテュート |
Ｈｂｖ感染に対する抗ウイルス剤としてのスルファモイルベンズアミド誘導体
|
|
KR101939710B1
(ko)
|
2011-12-21 |
2019-01-17 |
노비라 테라퓨틱스, 인코포레이티드 |
B형 간염의 항바이러스성 제제
|
|
JP6134338B2
(ja)
|
2012-02-29 |
2017-05-24 |
バルーク エス．ブルームバーグ インスティテュート |
Ｂ型肝炎ウイルス共有結合閉環状ｄｎａ形成の阻害剤およびそれらの使用方法
|
|
WO2013144129A1
(en)
|
2012-03-31 |
2013-10-03 |
F. Hoffmann-La Roche Ag |
Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
|
|
US20130267517A1
(en)
|
2012-03-31 |
2013-10-10 |
Hoffmann-La Roche Inc. |
Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
|
|
UY34993A
(es)
|
2012-08-28 |
2014-02-28 |
Janssen R & D Ireland |
Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
|
|
CN104797561B
(zh)
|
2012-08-28 |
2017-03-01 |
爱尔兰詹森科学公司 |
稠合二环的氨磺酰基衍生物及其作为药物用于治疗乙型肝炎的用途
|
|
AU2013355220B2
(en)
|
2012-12-06 |
2018-08-02 |
Baruch S. Blumberg Institute |
Functionalized benzamide derivatives as antiviral agents against HBV infection
|
|
CA2896554C
(en)
|
2012-12-27 |
2019-11-05 |
Drexel University |
Novel antiviral agents against hbv infection
|
|
WO2014131847A1
(en)
|
2013-02-28 |
2014-09-04 |
Janssen R&D Ireland |
Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
|
|
US8993771B2
(en)
|
2013-03-12 |
2015-03-31 |
Novira Therapeutics, Inc. |
Hepatitis B antiviral agents
|
|
JP6419155B2
(ja)
|
2013-04-03 |
2018-11-07 |
ヤンセン・サイエンシズ・アイルランド・ユーシー |
Ｎ−フェニル−カルボキサミド誘導体およびｂ型肝炎を治療するための医薬品としてのその使用
|
|
JO3583B1
(ar)
|
2013-05-17 |
2020-07-05 |
Janssen Sciences Ireland Uc |
مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
|
|
HRP20181863T1
(hr)
|
2013-05-17 |
2018-12-28 |
Janssen Sciences Ireland Uc |
Derivati sulfamoiltiofenamida i njihova uporaba kao lijekova za liječenje hepatitisa b
|
|
NO3024819T3
(enExample)
|
2013-07-25 |
2018-07-21 |
|
|
|
MX368158B
(es)
|
2013-10-23 |
2019-09-20 |
Janssen Sciences Ireland Uc |
Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
|
|
HK1223094A1
(zh)
|
2013-11-14 |
2017-07-21 |
Novira Therapeutics Inc. |
氮杂环庚烷衍生物和治疗乙型肝炎感染的方法
|
|
US9169212B2
(en)
|
2014-01-16 |
2015-10-27 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
|
JP2017504633A
(ja)
|
2014-01-30 |
2017-02-09 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Ｂ型肝炎ウイルス感染の治療及び予防のための新規なジヒドロキノリジノン
|
|
DK3102572T3
(en)
|
2014-02-06 |
2019-02-04 |
Janssen Sciences Ireland Uc |
SULFAMOYLPYRROLAMIDE DERIVATIVES AND THEIR USE AS MEDICINES TO TREAT HEPATITIS B
|
|
ES2714110T3
(es)
|
2014-03-07 |
2019-05-27 |
Hoffmann La Roche |
Heteroarildihidropirimidinas 6-fusionadas novedosas para el tratamiento y profilaxis de la infección por el virus de la hepatitis B
|
|
CN110437153A
(zh)
|
2014-03-13 |
2019-11-12 |
美国印第安纳大学研究和技术公司 |
乙型肝炎核心蛋白变构调节剂
|
|
CA2948080A1
(en)
|
2014-05-13 |
2015-11-19 |
F. Hoffmann-La Roche Ag |
Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
|
|
CN106459061B
(zh)
|
2014-05-30 |
2020-01-21 |
齐鲁制药有限公司 |
作为hbv抑制剂的二氢嘧啶并环衍生物
|
|
CN106573898B
(zh)
|
2014-08-14 |
2018-11-09 |
豪夫迈·罗氏有限公司 |
治疗和预防乙型肝炎病毒感染的新的哒嗪酮和三嗪酮
|
|
US9637485B2
(en)
|
2014-11-03 |
2017-05-02 |
Hoffmann-La Roche Inc. |
6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
|
|
ES2802412T3
(es)
|
2014-12-02 |
2021-01-19 |
Novira Therapeutics Inc |
Compuestos de sulfonamida inversa a base de sulfuro, alquilo y piridilo para el tratamiento del VHB
|
|
CN107108610B
(zh)
|
2014-12-30 |
2019-06-04 |
豪夫迈·罗氏有限公司 |
用于治疗和预防肝炎b病毒感染的新的四氢吡啶并嘧啶和四氢吡啶并吡啶化合物
|
|
EP3256471B1
(en)
|
2015-02-11 |
2018-12-12 |
F. Hoffmann-La Roche AG |
Novel 2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
|
|
EP3256461B1
(en)
*
|
2015-02-13 |
2023-09-13 |
Azienda Ospedaliera Universitaria Senese |
Urea and sulfonamide derivatives as human helicase ddx3 inhibitors useful in the treatment of viral diseases
|
|
EP3292120B1
(en)
|
2015-05-04 |
2019-06-19 |
H. Hoffnabb-La Roche Ag |
Tetrahydropyridopyrimidines and tetrahydropyridopyridines as inhibitors of hbsag (hbv surface antigen) and hbv dna production for the treatment of hepatitis b virus infections
|
|
WO2016183266A1
(en)
|
2015-05-13 |
2016-11-17 |
Enanta Pharmaceuticals, Inc. |
Ehpatitis b antiviral agents
|
|
US10179131B2
(en)
|
2015-07-13 |
2019-01-15 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
|
CN107849037B
(zh)
|
2015-07-21 |
2020-04-17 |
豪夫迈·罗氏有限公司 |
用于治疗和预防乙型肝炎病毒感染的三环4-吡啶酮-3-甲酸衍生物
|
|
WO2017015451A1
(en)
|
2015-07-22 |
2017-01-26 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
|
WO2017016960A1
(en)
|
2015-07-24 |
2017-02-02 |
F. Hoffmann-La Roche Ag |
Process for the preparation of (6s)-6-alkyl-10-alkoxy-9-(substituted alkoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid analogues
|
|
WO2017016921A1
(en)
|
2015-07-24 |
2017-02-02 |
F. Hoffmann-La Roche Ag |
New crystalline forms of (6s)-10-methoxy-6-isopropyl-9-(3-methoxypropoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid
|
|
WO2017017042A1
(en)
|
2015-07-27 |
2017-02-02 |
F. Hoffmann-La Roche Ag |
Novel tetracyclic 4-oxo-pyridine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
|
|
JP6559324B2
(ja)
|
2015-07-28 |
2019-08-14 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Ｂ型肝炎ウイルス感染の治療及び予防用の新規６，７−ジヒドロピリド［２，１−ａ］フタラジン−２−オン類
|
|
TWI721016B
(zh)
|
2015-09-15 |
2021-03-11 |
美商艾森伯利生物科學公司 |
B型肝炎核心蛋白質調節劑
|
|
WO2017064156A1
(en)
|
2015-10-16 |
2017-04-20 |
F. Hoffmann-La Roche Ag |
Novel 6-fused and 2-heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
|
|
WO2017102648A1
(en)
|
2015-12-15 |
2017-06-22 |
F. Hoffmann-La Roche Ag |
Combination therapy of an hbsag inhibitor and a nucleos(t)ide analogue
|
|
MA44075A
(fr)
|
2015-12-17 |
2021-05-19 |
Incyte Corp |
Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
|
|
WO2017108630A1
(en)
|
2015-12-21 |
2017-06-29 |
F. Hoffmann-La Roche Ag |
Combination therapy of an hbsag inhibitor and an hbv capsid assembly inhibitor
|
|
WO2017114812A1
(en)
|
2015-12-29 |
2017-07-06 |
F. Hoffmann-La Roche Ag |
Combination therapy of an hbsag inhibitor and an interferon
|
|
ES2897913T3
(es)
|
2016-02-19 |
2022-03-03 |
Novartis Ag |
Compuestos de piridona tetracíclicos como antivirales
|
|
JP2019530732A
(ja)
|
2016-08-03 |
2019-10-24 |
アライジング・インターナショナル・インコーポレイテッドＡｒｉｓｉｎｇ Ｉｎｔｅｒｎａｔｉｏｎａｌ， Ｉｎｃ． |
免疫モジュレータとして有用な対称または半対称化合物
|
|
WO2018044783A1
(en)
|
2016-08-29 |
2018-03-08 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
US10144706B2
(en)
|
2016-09-01 |
2018-12-04 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
|
WO2018045142A1
(en)
|
2016-09-02 |
2018-03-08 |
Polaris Pharmaceuticals, Inc. |
Immune checkpoint inhibitors, compositions and methods thereof
|
|
CN116751200A
(zh)
|
2016-11-07 |
2023-09-15 |
爱彼特生物制药公司 |
含有取代的吡啶酮的三环化合物以及使用其的方法
|
|
JP7106572B2
(ja)
|
2016-12-20 |
2022-07-26 |
ブリストル－マイヤーズ スクイブ カンパニー |
免疫調節剤として有用な化合物
|
|
EP3558973B1
(en)
|
2016-12-22 |
2021-09-15 |
Incyte Corporation |
Pyridine derivatives as immunomodulators
|
|
EP3558989B1
(en)
|
2016-12-22 |
2021-04-14 |
Incyte Corporation |
Triazolo[1,5-a]pyridine derivatives as immunomodulators
|
|
PE20191532A1
(es)
|
2016-12-22 |
2019-10-23 |
Incyte Corp |
Compuestos heterociclicos como inmunomoduladores
|
|
CA3047991A1
(en)
|
2016-12-22 |
2018-06-28 |
Incyte Corporation |
Bicyclic heteroaromatic compounds as immunomodulators
|
|
EP3564237A4
(en)
|
2016-12-29 |
2020-06-10 |
Shenzhen Chipscreen Biosciences Co., Ltd. |
UREA COMPOUND AND PRODUCTION METHOD AND USE THEREOF
|
|
CN109678796B
(zh)
|
2017-10-19 |
2023-01-10 |
上海长森药业有限公司 |
Pd-1/pd-l1小分子抑制剂及其制备方法和用途
|
|
BR112020008851A2
(pt)
|
2017-11-06 |
2020-10-20 |
Jubilant Prodel LLC |
composto da fórmula i, processo de preparação de compostos da fórmula i, composição farmacêutica, método para o tratamento e/ou prevenção de várias doenças, uso, método para o tratamento de câncer, método de tratamento de câncer e método para o tratamento e/ou prevenção de câncer e doenças infecciosas
|
|
TW202214574A
(zh)
*
|
2020-06-08 |
2022-04-16 |
加拿大商愛彼特生物製藥公司 |
經取代之(呔-1-基甲基)脲類、經取代之n-(呔-1-基甲基)醯胺類及其類似物
|